PulseSight Therapeutics

Background

PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.

Back to Portfolio

Latest News

BIOTECH

AUM Biosciences, SCG Cell Therapy, Blood And Hello Health Disclose Updates

BIOTECH

AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V

BIOTECH

AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene

BIOTECH

AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies

All news

Creating Solutions Together.

Contact Us